2017 U.S. ASPIRE Hemophilia Research Awards Program

Funding Agency:
Pfizer Inc.

The 2017 U.S. Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia to support ongoing basic science and clinical investigation in hemophilia A and B.

Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia A and hemophilia B and their related comorbidities. In an era of increased competition for research funding, the 2017 U.S. ASPIRE Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of hemophilia A and B.

Mission

  • To advance basic science, translational and clinical research through a competitive grants program that increases medical knowledge in the pathogenesis, complications, management, and clinical outcomes of hemophilia A and B.
  • To support academic research as well as the career development of promising young and established scientists.

Deadline: Mar. 31, 2017

Agency Website

Eligibility Requirements

To be eligible:

  • The study must take place entirely in the US, and all sites must be located in the US. The Principle Investigator (PI) and sponsoring organization must be located in the United States.
  • The applicant (PI) must have a medical degree (MD or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.

Note: Current external review panel members are not eligible to apply, either as applicant or co-applicant. Serving as a mentor, however, to an applicant is permitted

Amount

$100,000

Funding Type

Grant

Eligibility

Faculty
Junior Faculty
Medical Fellow/Resident
Post Doctoral Fellows

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 31, 2017